Log in

NYSE:CRY - Cryolife Stock Price, Forecast & News

$15.52
-0.74 (-4.55 %)
(As of 03/29/2020 02:30 AM ET)
Today's Range
$15.15
Now: $15.52
$16.95
50-Day Range
$14.66
MA: $24.17
$30.57
52-Week Range
$12.63
Now: $15.52
$33.00
Volume623,319 shs
Average Volume432,314 shs
Market Capitalization$606.52 million
P/E Ratio388.10
Dividend YieldN/A
Beta0.86
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft system for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Read More
Cryolife logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP22890310
Phone770-419-3355

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$276.22 million
Cash Flow$0.76 per share
Book Value$7.62 per share

Profitability

Net Income$1.72 million

Miscellaneous

Employees1,200
Market Cap$606.52 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter.


Cryolife (NYSE:CRY) Frequently Asked Questions

How has Cryolife's stock been impacted by COVID-19 (Coronavirus)?

Cryolife's stock was trading at $23.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRY stock has decreased by 35.0% and is now trading at $15.52. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cryolife?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cryolife.

When is Cryolife's next earnings date?

Cryolife is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Cryolife.

How were Cryolife's earnings last quarter?

Cryolife Inc (NYSE:CRY) released its quarterly earnings results on Thursday, February, 13th. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03. The medical equipment provider had revenue of $69.70 million for the quarter, compared to analysts' expectations of $72.95 million. Cryolife had a net margin of 0.62% and a return on equity of 4.16%. View Cryolife's earnings history.

What guidance has Cryolife issued on next quarter's earnings?

Cryolife updated its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $0.15-0.17 for the period, compared to the Thomson Reuters consensus estimate of $0.38. The company issued revenue guidance of $292-298 million, compared to the consensus revenue estimate of $299.19 million.

What price target have analysts set for CRY?

4 analysts have issued 1-year price objectives for Cryolife's stock. Their forecasts range from $29.00 to $38.00. On average, they anticipate Cryolife's share price to reach $33.67 in the next twelve months. This suggests a possible upside of 116.9% from the stock's current price. View analysts' price targets for Cryolife.

Has Cryolife been receiving favorable news coverage?

Media coverage about CRY stock has trended negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cryolife earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutCryolife.

Who are some of Cryolife's key competitors?

What other stocks do shareholders of Cryolife own?

Who are Cryolife's key executives?

Cryolife's management team includes the following people:
  • Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
  • Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
  • Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
  • Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
  • Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)

What is Cryolife's stock symbol?

Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

Who are Cryolife's major shareholders?

Cryolife's stock is owned by a number of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (4.47%), Macquarie Group Ltd. (4.47%), Capital Research Global Investors (4.11%), State Street Corp (3.47%), ArrowMark Colorado Holdings LLC (2.72%) and Loomis Sayles & Co. L P (1.94%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View institutional ownership trends for Cryolife.

Which institutional investors are selling Cryolife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Monarch Partners Asset Management LLC, Renaissance Technologies LLC, Nuveen Asset Management LLC, THB Asset Management, Brasada Capital Management LP, Arizona State Retirement System, and Bank of America Corp DE. Company insiders that have sold Cryolife company stock in the last year include David Ashley Lee, James P Mackin, Jean F Holloway, Ronald D Mccall, and Scott B Capps. View insider buying and selling activity for Cryolife.

Which institutional investors are buying Cryolife stock?

CRY stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Capital Research Global Investors, William Blair Investment Management LLC, Penn Capital Management Co. Inc., State Street Corp, Goldman Sachs Group Inc., Thrivent Financial for Lutherans, and Great West Life Assurance Co. Can. View insider buying and selling activity for Cryolife.

How do I buy shares of Cryolife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cryolife's stock price today?

One share of CRY stock can currently be purchased for approximately $15.52.

How big of a company is Cryolife?

Cryolife has a market capitalization of $606.52 million and generates $276.22 million in revenue each year. The medical equipment provider earns $1.72 million in net income (profit) each year or $0.31 on an earnings per share basis. Cryolife employs 1,200 workers across the globe. View additional information about Cryolife.

What is Cryolife's official website?

The official website for Cryolife is http://www.cryolife.com/.

How can I contact Cryolife?

Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]


MarketBeat Community Rating for Cryolife (NYSE CRY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel